Translate bio, inc. (TBIO)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities:
Net loss

-14,282

-31,036

-21,227

-27,832

-33,198

-6,037

-42,646

-27,503

-21,209

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

1,351

1,781

991

935

1,025

918

476

911

536

Stock-based compensation expense

3,172

2,926

2,899

3,550

1,959

1,640

1,435

2,875

1,383

Change in fair value of contingent consideration

-9,452

3,256

-19,834

4,889

11,702

-14,569

26,829

7,852

4,908

Deferred income tax benefit

-

0

0

0

-486

-439

-2,524

-1,499

-1,103

Accretion of discount on short-term investments

-

-

-

-

-

-

-

-1

-42

Changes in operating assets and liabilities:
Collaboration receivables

-1,633

-

-

-

-482

-

-

-

-

Prepaid expenses and other assets

397

3,710

3,019

1,481

285

-256

-907

530

1,979

Right-of-use assets

-132

-127

-123

-119

-115

-

-

-

-

Accounts payable

-9,545

11,668

118

-810

-1,048

2,251

-2,674

-450

1,531

Accrued expenses

584

-1,987

1,644

671

-71

877

1,128

1,670

-1,404

Deferred rent

-

-

-

-

-

41

42

25

362

Lease liability

-110

-105

-100

-96

-74

-

-

-

-

Deferred revenue

-1,267

581

-609

-341

-688

-

-

-

-

Net cash used in operating activities

-31,447

-20,262

-20,455

-19,914

-21,531

-16,244

27,692

-16,648

-16,933

Cash flows from investing activities:
Purchases of investments

27,409

-

-

-

-

8,381

122,313

0

6,000

Sales and maturities of investments

73,994

43,311

60,555

26,851

28,905

41,986

1,080

5,000

9,918

Purchases of property and equipment

2,325

1,296

448

754

1,039

1,013

810

1,851

2,906

Net cash provided by investing activities

44,260

5,900

-39,611

-12,341

27,866

32,592

-122,043

3,149

1,012

Cash flows from financing activities:
Payments of public offering costs

57

-

-

-

-

-

-

-

-

Payments of initial public offering costs

-

-

-

-

-

13

1,668

1,082

1,339

Proceeds from option exercises

132

12

84

519

897

-

-

-

-

Net cash provided by financing activities

75

12

84,092

44,653

897

-13

115,779

-804

-1,339

Net increase in cash, cash equivalents and restricted cash

12,888

-14,350

24,026

12,398

7,232

16,335

21,428

-14,303

-17,260

Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses

764

1,187

-57

-36

95

-314

-126

-227

716

Deferred offering costs included in accounts payable and accrued expenses

120

-

-

-

-

-

-1,389

476

926

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

0

0

459

185